MannKind

MannKind - Afrezza Scripts Come Back Down After ADA Conference Bump
MannKind - Afrezza Scripts Come Back Down After ADA Conference Bump
Seeking Alpha
Afrezza
MannKind
diabetes
inhaled insulin
Flag link:
MannKind: Afrezza Sales See Best Result In More Than A Year
MannKind: Afrezza Sales See Best Result In More Than A Year
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
MannKind’s Afrezza needs a big turn. Can reality TV and a new commercial get it done?
MannKind’s Afrezza needs a big turn. Can reality TV and a new commercial get it done?
Fierce Pharma
MannKind
Afrezza
diabetes
television ads
drug marketing
Flag link:
MannKind Scripts Not Helping Cash Situation
MannKind Scripts Not Helping Cash Situation
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
MannKind inks deal to bring inhaled insulin to Brazil
MannKind inks deal to bring inhaled insulin to Brazil
Drug Delivery Business News
MannKind
Brazil
diabetes
inhaled insulin
Afrezza
Flag link:
One Drop, MannKind ink partnership for connected, inhaled diabetes tech
One Drop, MannKind ink partnership for connected, inhaled diabetes tech
Drug Delivery Business News
One Drop
MannKind
inhaled insulin
diabetes
devices
Afrezza
Flag link:
MannKind Hopes To Reverse Fortunes With Television Show
MannKind Hopes To Reverse Fortunes With Television Show
Seeking Alpha
MannKind
television ads
diabetes
type 2 diabetes
DTC advertising
Flag link:
Is MannKind Corporation Getting Ready to Sell?
Is MannKind Corporation Getting Ready to Sell?
Motley Fool
MannKind
M&A
SEC
Flag link:
MannKind: Afrezza Sales Remain Low As Q1 Comes To A Close
MannKind: Afrezza Sales Remain Low As Q1 Comes To A Close
Seeking Alpha
MannKind
Afrezza
inhaled insulin
diabetes
Flag link:
Could MannKind Corporation's Marketing Blitz Pay Off?
Could MannKind Corporation's Marketing Blitz Pay Off?
Motley Fool
MannKind
Afrezza
diabetes
inhaled insulin
Sanofi
drug ads
Flag link:
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
Motley Fool
MannKind
diabetes
inhaled insulin
Afrezza
Flag link:
Can MannKind Be Saved?
Can MannKind Be Saved?
Barron's
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
MannKind Attempts to Revive Afrezza Sales
MannKind Attempts to Revive Afrezza Sales
Investopedia
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
Afrezza Sales Still Low As MannKind Prepares For Investor Update
Afrezza Sales Still Low As MannKind Prepares For Investor Update
Seeking Alpha
Afrezza
MannKind
diabetes
inhaled insulin
Flag link:
MannKind: Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make A Material Difference?
MannKind: Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make A Material Difference?
Seeking Alpha
MannKind
Afrezza
diabetes
drug reps
inhaled insulin
Flag link:
JPM: Day 4 round-up
JPM: Day 4 round-up
BioPharma Dive
JPMHC 2017
Novavax
Tesaro
MannKind
Flag link:
MannKind's $1M Milestone: Good News, But Barely
MannKind's $1M Milestone: Good News, But Barely
Seeking Alpha
MannKind
diabetes
Receptor Life Sciences
Flag link:
MannKind Receives $1 Million Milestone From RLS
MannKind Receives $1 Million Milestone From RLS
Yahoo
MannKind
Receptor Life Sciences
Flag link:
Mannkind's Afrezza Is Fizzling Out
Mannkind's Afrezza Is Fizzling Out
Seeking Alpha
MannKind
Afrezza
diabetes
inhaled insulin
Flag link:
2 Key Reasons MannKind Needs To Remain On Nasdaq
2 Key Reasons MannKind Needs To Remain On Nasdaq
Seeking Alpha
MannKind
diabetes
NASDAQ
Afrezza
Flag link: